XML 103 R85.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]      
Income (loss) before income taxes $ (3,065) $ 658 $ (4,406)
Statutory tax rate in Israel 23.00% 23.00% 23.00%
Theoretical provision for income taxes $ (705) $ 151 $ (1,013)
Increase (decrease) in the provision for income taxes due to:      
The Parent Company and its Israeli subsidiaries - Tax benefits arising from reduced tax rates under benefit programs 15 (12) (153)
Mainly nondeductible items and prior year tax 35 20 (30)
Non-Israeli subsidiaries, including impairments [1] 924 117 1,369
Worthless stock deduction [2] (909)    
Increase (decrease) in other uncertain tax positions—net 2 (65) (341)
Effective consolidated income taxes $ (638) $ 211 $ (168)
[1] In 2022 and 2020, loss before income taxes includes goodwill impairment in non-Israeli subsidiaries that did not have a corresponding tax effect.
[2] In 2022, one of Teva’s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva will recognize on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with related tax benefit of approximately $909 million.